New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOvagen vs Teduglutide

Ovagen vs Teduglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Ovagen
Recovery & Repair
Teduglutide
Summary
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2 hours; once-daily dosing due to gut-specific residence
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
0.05 mg/kg/day
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
  • Increases intestinal villus height and absorption surface area
  • Reduces intestinal permeability (leaky gut)
  • FDA-approved for short bowel syndrome
  • Reduces parenteral nutrition dependence in SBS patients
  • Promotes intestinal mucosal healing in IBD
  • Increases tight junction proteins ZO-1 and occludin
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
  • Injection site reactions
  • Abdominal pain and bloating
  • Nausea
  • Risk of intestinal polyp growth (requires colonoscopy surveillance)
  • +1 more
Stacks With